Media Room Menu
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Sep 18, 2019Understand AD program brings together a team of experts to help a teen with severe atopic dermatitis (AD) and his parents navigate the disease
-
Aug 28, 2019Court rules in favor of Sanofi and Regeneron in ongoing Praluent® (alirocumab) patent litigation
-
Aug 6, 2019U.S. FDA submission for children planned for 4Q 2019
-
Jun 26, 2019* First biologic medicine for adults with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP)
-
Jun 2, 2019News Summary: * Isatuximab, an investigational anti-CD38 monoclonal antibody, added to pomalidomide and dexamethasone prolonged progression free survival by 5 months compared to pomalidomide and dexamethasone alone (11.53 vs. 6.47 months, p=0.001, HR 0.596) * Overall response rate significantly greater with isatuximab combination therapy compared to pomalidomide and dexamethasone (60% vs. 35%, p<0.0001) * First positive randomized Phase 3 trial to evaluate an antibody in combination with pomalidomide and dexamethasone presented at this year’s ASCO annual meeting * European Medicines Agency accepted for review the Marketing Authorization Application for isatuximab
-
May 15, 2019- Pivotal Phase 3 data evaluated isatuximab (anti-CD38) in combination with pomalidomide/dexamethasone in prolonging progression-free survival in relapsed/refractory multiple myeloma
-
May 15, 2019* New data at ASCO include more than double the patients previously reported; median overall survival still not reached with a median follow-up of up to 17 months
-
May 7, 2019* Only biologic approved in the EU for severe asthma with type 2 inflammation, as characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO)
-
Apr 26, 2019* Praluent is the first PCSK9 inhibitor that has shown a meaningful reduction in death from any cause
-
Apr 10, 2019* Sanofi continues its commitment to helping reduce cost burden for people living with diabetes with first-ever insulin savings program
-
Mar 11, 2019* Only therapy that targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis
-
Feb 27, 2019* Soliqua 100/33 now approved as an add-on to diet and exercise for adults with type 2 diabetes
-
Feb 25, 2019Praluent® (alirocumab) continues to be available in the U.S.
-
Feb 11, 2019* This is the latest step by the companies to help make Praluent more accessible and affordable for appropriate patients
-
Feb 6, 2019- First medicine approved in the U.S. specifically for the treatment of aTTP, a rare blood-clotting disorder
-
Jan 23, 2019- The 0.5 mL dose is now approved for use in children 6 months through 35 months of age
-
Jan 14, 2019* First and only vaccine approved in the U.S. for repeat vaccination 8 years or more after the first vaccination to help protect against tetanus, diphtheria and pertussis, offering flexibility for health care providers to help manage their immunization schedules(2)
-
Jan 9, 2019-HERCULES Phase 3 trial met its primary endpoint, demonstrating that treatment with Cablivi resulted in a significantly faster time to platelet count response in patients with acquired thrombotic thrombocytopenic purpura (aTTP) when administered in conjunction with plasma exchange and immunosuppression
-
Nov 11, 2018* Mortality risk reduction greater in patients treated for at least 3 years or those with baseline LDL-C levels of at least 100 mg/dL
-
Nov 7, 2018* Praluent significantly reduced major adverse cardiovascular events by 15% (p<0.001)
-
Oct 19, 2018-- Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype
-
Oct 16, 2018- Dupixent significantly reduced nasal polyp size, nasal congestion severity, and need for systemic corticosteroids and/or surgery
-
Sep 28, 2018* Libtayo is the third anti-PD-1 approved in the U.S.
-
Sep 12, 2018* FDA also recently approved Praluent label update for some patients currently requiring LDL apheresis therapy
-
Jun 4, 2018-- Patients treated with cemiplimab experienced robust anti-tumor effects
-
May 21, 2018* In steroid-sparing VENTURE trial, Dupixent-treated patients substantially reduced use of oral corticosteroids, yet had fewer exacerbations and improved lung function compared to placebo.
-
May 16, 2018* U.S. regulatory submission for patients ages 12-17 planned for third quarter 2018
-
May 1, 2018-- Agreement provides Praluent at lower net price and enables streamlined patient access based on physician attestation
-
Apr 25, 2018- If approved, health care professionals will be able to use the same 0.5 mL dose of Fluzone Quadrivalent vaccine with all patients ages 6 months and older for whom flu vaccination is recommended - which may provide more flexibility and convenience to immunizers.
-
Mar 27, 2018* Max SoloStar holds more insulin than any other long-acting insulin pen
-
Mar 27, 2018- Sanofi teams up with television personality Adam Savage and allergist Dr. Neeta Ogden to help dispel common allergy misconceptions with facts
-
Mar 10, 2018* Precision medicine approach will focus efforts on high-risk patients, such as those who have had heart attacks or unstable angina and cannot reduce their LDL-C below 100 mg/dL despite maximally-tolerated statins
-
Mar 10, 2018* ODYSSEY OUTCOMES trial met its primary endpoint, demonstrating that high-risk patients who added Praluent® (alirocumab) Injection to maximally-tolerated statins experienced significantly fewer major adverse cardiovascular events compared to those on maximally-tolerated statins alone
-
Jan 8, 2018Companies also announce submission of dupilumab supplemental BLA for uncontrolled, persistent asthma
-
Oct 31, 2017First study with a biologic to show benefit in severe steroid-dependent asthma population that enrolled patients regardless of blood eosinophil levels or any other Type 2 biomarkers at baseline
-
Oct 16, 2017- Late-breaking oral abstract presented at the World Congress of Gastroenterology -
-
Oct 5, 2017- Praluent continues to be available to patients in the U.S. -